专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP0290516A1 PULMONARY HYDROPHOBIC SURFACTANT-ASSOCIATED PROTEINS 失效
标题翻译：与表面活性疏水LUNG剂蛋白连接。
公开(公告)号：EP0290516A1
公开(公告)日：1988-11-17
申请号：EP87907365.0
申请日：1987-10-02
申请人： WHITSETT, Jeffrey A. , FOX, J. Lawrence , PILOT-MATIAS, Tami J. , MEUTH, Joseph L. , SARIN, Virender K.
发明人： WHITSETT, Jeffrey A. , FOX, J. Lawrence , PILOT-MATIAS, Tami J. , MEUTH, Joseph L. , SARIN, Virender K.
IPC分类号： A61K31 , A61K35 , A61K38 , C07K14 , C07K16 , C12N9 , C12N15
CPC分类号： A61K31/685 , A61K31/575 , A61K31/66 , A61K35/42 , A61K38/1709 , C07K14/785 , C07K16/18 , C07K2319/00 , C07K2319/035 , C12N9/00 , C12N15/72 , A61K2300/00
摘要： Novel, isolated, substantially pure, hydrophobic surfactant-associated proteins of 4,000-7,000 dalton simple molecular weight, SAP(Val) and SAP(Phe); multimers thereof, and substitution, addition and deletion analogs and fragments thereof. When SAP(Val) and/or SAP(Phe) is combined with lipids, its surfactant-like property imparts to the combination significant pulmonary biophysical activity. Such a combination results in enhanced adsorption of the lipids with properties similar to that of natural pulmonary surfactant material. SAP(Val) and/or SAP(Phe) in combination with lipids is highly useful for replacing or supplementing natural pulmonary surfactant material for reducing or maintaining normal surface tension in the lungs, especially in the lungs of patients suffering from hyaline membrane disease, HMD, or other syndromes associated with the lack or insufficient amounts of natural pulmonary surfactant material. A combination of SAP(Val) and/or SAP(Phe) and lipids may be administered as an aerosol spray or in aqueous normal saline with or without calcium chloride for treating or preventing HMD and other surfactant deficiency states. Also disclosed are methods of isolating the SAP(Val) from animal tissue and methods for making SAP(Val) and SAP(Phe) by recombinant DNA techniques and direct peptide synthesis; genomic clones of SAP(Val) and SAP(Phe); expression systems and products for SAP(Val) DNA; and polyclonal and monoclonal antibodies to SAP(Val) and SAP(Phe).

2. 发明公开

EP0290516A4 PULMONARY HYDROPHOBIC SURFACTANT-ASSOCIATED PROTEINS. 失效
标题翻译：与表面活性疏水LUNG剂蛋白连接。
公开(公告)号：EP0290516A4
公开(公告)日：1989-11-14
申请号：EP87907365
申请日：1987-10-02
申请人： WHITSETT JEFFREY A , FOX J LAWRENCE , PILOT MATIAS TAMI J , MEUTH JOSEPH L , SARIN VIRENDER K
发明人： WHITSETT JEFFREY A
IPC分类号： A61K31/575 , A61K31/66 , A61K31/685 , A61K35/42 , A61K38/00 , A61K38/17 , C07K14/785 , C07K16/18 , C12N9/00 , C12N15/72
CPC分类号： A61K31/685 , A61K31/575 , A61K31/66 , A61K35/42 , A61K38/1709 , C07K14/785 , C07K16/18 , C07K2319/00 , C07K2319/035 , C12N9/00 , C12N15/72 , A61K2300/00
摘要： Novel, isolated, substantially pure, hydrophobic surfactant-associated proteins of 4,000-7,000 dalton simple molecular weight, SAP(Val) and SAP(Phe); multimers thereof, and substitution, addition and deletion analogs and fragments thereof. When SAP(Val) and/or SAP(Phe) is combined with lipids, its surfactant-like property imparts to the combination significant pulmonary biophysical activity. Such a combination results in enhanced adsorption of the lipids with properties similar to that of natural pulmonary surfactant material. SAP(Val) and/or SAP(Phe) in combination with lipids is highly useful for replacing or supplementing natural pulmonary surfactant material for reducing or maintaining normal surface tension in the lungs, especially in the lungs of patients suffering from hyaline membrane disease, HMD, or other syndromes associated with the lack or insufficient amounts of natural pulmonary surfactant material. A combination of SAP(Val) and/or SAP(Phe) and lipids may be administered as an aerosol spray or in aqueous normal saline with or without calcium chloride for treating or preventing HMD and other surfactant deficiency states. Also disclosed are methods of isolating the SAP(Val) from animal tissue and methods for making SAP(Val) and SAP(Phe) by recombinant DNA techniques and direct peptide synthesis; genomic clones of SAP(Val) and SAP(Phe); expression systems and products for SAP(Val) DNA; and polyclonal and monoclonal antibodies to SAP(Val) and SAP(Phe).

3. 发明申请

WO2008133753A2 ANTI-VIRAL COMPOUNDS 审中-公开
标题翻译：反虚构化合物
公开(公告)号：WO2008133753A2
公开(公告)日：2008-11-06
申请号：PCT/US2007/088027
申请日：2007-12-19
申请人： ABBOTT LABORATORIES , BETEBENNER, David A. , MARING, Clarence J. , ROCKWAY, Todd W. , COOPER, Curt S. , ANDERSON, David D. , WAGNER, Rolf , ZHANG, Rong , MOLLA, Akhteruzzaman , MO, Hongmei , PILOT-MATIAS, Tami J. , MASSE, Sherie Vl. , CARRICK, Robert J. , HE, Wenping , LU, Liangjun
发明人： BETEBENNER, David A. , MARING, Clarence J. , ROCKWAY, Todd W. , COOPER, Curt S. , ANDERSON, David D. , WAGNER, Rolf , ZHANG, Rong , MOLLA, Akhteruzzaman , MO, Hongmei , PILOT-MATIAS, Tami J. , MASSE, Sherie Vl. , CARRICK, Robert J. , HE, Wenping , LU, Liangjun
IPC分类号： A61K31/675
CPC分类号： C07D471/04 , C07D239/94 , C07D487/04 , C07D487/14 , C07D519/00
摘要： Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
摘要翻译：公开了有效抑制丙型肝炎病毒（HCV）或其他病毒复制的化合物。本发明还涉及包含这些化合物的组合物，这些化合物与其它抗病毒剂或治疗剂的共配制或共同给药，用于合成这些化合物的方法和中间体，以及使用这些化合物治疗HCV或其他病毒感染。

4. 发明申请

WO2007081517A2 ANTI-VIRAL COMPOUNDS 审中-公开
公开(公告)号：WO2007081517A2
公开(公告)日：2007-07-19
申请号：PCT/US2006/048685
申请日：2006-12-20
申请人： ABBOTT LABORATORIES , BETEBENNER, David, A. , DEGOEY, David, A. , MARING, Clarence, J. , KRUEGER, Allan, C. , IWASAKI, Nobuhiko , ROCKWAY, Todd, W. , COOPER, Curt, S. , ANDERSON, David, D. , DONNER, Pamela, L. , GREEN, Brian, E. , KEMPF, Dale, J. , LIU, Dachun , MCDANIEL, Keith, F. , MADIGAN, Darold, L. , MOTTER, Christopher, E. , PRATT, John, K. , SHANLEY, Jason, P. , TUFANO, Michael, D. , WAGNER, Rolf , ZHANG, Rong , MOLLA, Akhteruzzaman , MO, Hongmei , PILOT-MATIAS, Tami, J. , MASSE, Sherie, VL. , CARRICK, Robert, J. , HE, Weping , LU, Liangjun , GRAMPOVNIK, David, J.
发明人： BETEBENNER, David, A. , DEGOEY, David, A. , MARING, Clarence, J. , KRUEGER, Allan, C. , IWASAKI, Nobuhiko , ROCKWAY, Todd, W. , COOPER, Curt, S. , ANDERSON, David, D. , DONNER, Pamela, L. , GREEN, Brian, E. , KEMPF, Dale, J. , LIU, Dachun , MCDANIEL, Keith, F. , MADIGAN, Darold, L. , MOTTER, Christopher, E. , PRATT, John, K. , SHANLEY, Jason, P. , TUFANO, Michael, D. , WAGNER, Rolf , ZHANG, Rong , MOLLA, Akhteruzzaman , MO, Hongmei , PILOT-MATIAS, Tami, J. , MASSE, Sherie, VL. , CARRICK, Robert, J. , HE, Weping , LU, Liangjun , GRAMPOVNIK, David, J.
IPC分类号： C07D495/04 , C07D471/04 , C07D513/04
CPC分类号： C07D487/04 , C07D471/04 , C07D475/06 , C07D495/04 , C07D513/04
摘要： Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

5. 发明申请

WO1988003170A1 PULMONARY HYDROPHOBIC SURFACTANT-ASSOCIATED PROTEINS 审中-公开
标题翻译：肺血浆表面活性剂相关蛋白
公开(公告)号：WO1988003170A1
公开(公告)日：1988-05-05
申请号：PCT/US1987002536
申请日：1987-10-02
申请人： WHITSETT, Jeffrey, A. , FOX, J., Lawrence , PILOT-MATIAS, Tami, J. , MEUTH, Joseph, L. , SARIN, Virender, K.
IPC分类号： C12P21/00
CPC分类号： A61K31/685 , A61K31/575 , A61K31/66 , A61K35/42 , A61K38/1709 , C07K14/785 , C07K16/18 , C07K2319/00 , C07K2319/035 , C12N9/00 , C12N15/72 , A61K2300/00
摘要： Novel, isolated, substantially pure, hydrophobic surfactant-associated proteins of 4,000-7,000 dalton simple molecular weight, SAP(Val) and SAP(Phe); multimers thereof, and substitution, addition and deletion analogs and fragments thereof. When SAP(Val) and/or SAP(Phe) is combined with lipids, its surfactant-like property imparts to the combination significant pulmonary biophysical activity. Such a combination results in enhanced adsorption of the lipids with properties similar to that of natural pulmonary surfactant material. SAP(Val) and/or SAP(Phe) in combination with lipids is highly useful for replacing or supplementing natural pulmonary surfactant material for reducing or maintaining normal surface tension in the lungs, especially in the lungs of patients suffering from hyaline membrane disease, HMD, or other syndromes associated with the lack or insufficient amounts of natural pulmonary surfactant material. A combination of SAP(Val) and/or SAP(Phe) and lipids may be administered as an aerosol spray or in aqueous normal saline with or without calcium chloride for treating or preventing HMD and other surfactant deficiency states. Also disclosed are methods of isolating the SAP(Val) from animal tissue and methods for making SAP(Val) and SAP(Phe) by recombinant DNA techniques and direct peptide synthesis; genomic clones of SAP(Val) and SAP(Phe); expression systems and products for SAP(Val) DNA; and polyclonal and monoclonal antibodies to SAP(Val) and SAP(Phe).
摘要翻译：具有4,000-7,000道尔顿简单分子量的新型，分离的，基本上纯的疏水表面活性剂相关蛋白质SAP（Val）和SAP（Phe）; 多聚体及其取代，添加和缺失类似物及其片段。当SAP（Val）和/或SAP（Phe）与脂质组合时，其表面活性剂样特性赋予组合显着的肺生物物理活性。这种组合导致具有与天然肺表面活性剂材料类似的性质的脂质的增强的吸附。与脂质组合的SAP（Val）和/或SAP（Phe）可用于替代或补充天然肺表面活性物质，以降低或维持肺中正常的表面张力，特别是在患有透明膜病的患者的肺中，HMD ，或与天然肺表面活性物质的量不足或不足量相关的其他综合征。 SAP（Val）和/或SAP（Phe）和脂质的组合可以作为气溶胶喷雾剂或含有或不含氯化钙的水性生理盐水施用，用于治疗或预防HMD和其它表面活性剂缺乏状态。还公开了将SAP（Val）与动物组织分离的方法和通过重组DNA技术和直接肽合成制备SAP（Val）和SAP（Phe）的方法; SAP（Val）和SAP（Phe）的基因组克隆; SAP（Val）DNA的表达系统和产品; 和针对SAP（Val）和SAP（Phe）的多克隆和单克隆抗体。

6. 发明申请

WO2010075380A1 ANTI-VIRAL COMPOUNDS 审中-公开
公开(公告)号：WO2010075380A1
公开(公告)日：2010-07-01
申请号：PCT/US2009/069188
申请日：2009-12-22
申请人： ABBOTT LABORATORIES , DEGOEY, David, A. , DONNER, Pamela, L. , KATI, Warren, M. , HUTCHINS, Charles, W. , KRUEGER, Allan, C. , RANDOLPH, John, T. , MOTTER, Christopher, E. , KRISHNAN, Preethi , MISTRY, Neeta, C. , PILOT-MATIAS, Tami, J. , PATEL, Sachin, V. , LI, Xiaoyan , SOLTWEDEL, Todd, N. , NELSON, Lissa, T.
发明人： DEGOEY, David, A. , DONNER, Pamela, L. , KATI, Warren, M. , HUTCHINS, Charles, W. , KRUEGER, Allan, C. , RANDOLPH, John, T. , MOTTER, Christopher, E. , KRISHNAN, Preethi , MISTRY, Neeta, C. , PILOT-MATIAS, Tami, J. , PATEL, Sachin, V. , LI, Xiaoyan , SOLTWEDEL, Todd, N. , NELSON, Lissa, T.
IPC分类号： C07D471/04 , A61K31/4375 , A61K31/519 , A61P31/14
CPC分类号： C07D471/04 , C07D239/48
摘要： Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

7. 发明申请

WO2007081517A3 ANTI-VIRAL COMPOUNDS 审中-公开
公开(公告)号：WO2007081517A3
公开(公告)日：2007-12-21
申请号：PCT/US2006048685
申请日：2006-12-20
申请人： ABBOTT LAB , BETEBENNER DAVID A , DEGOEY DAVID A , MARING CLARENCE J , KRUEGER ALLAN C , IWASAKI NOBUHIKO , ROCKWAY TODD W , COOPER CURT S , ANDERSON DAVID D , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , LIU DACHUN , MCDANIEL KEITH F , MADIGAN DAROLD L , MOTTER CHRISTOPHER E , PRATT JOHN K , SHANLEY JASON P , TUFANO MICHAEL D , WAGNER ROLF , ZHANG RONG , MOLLA AKHTERUZZAMAN , MO HONGMEI , PILOT-MATIAS TAMI J , MASSE SHERIE VL , CARRICK ROBERT J , HE WEPING , LU LIANGJUN , GRAMPOVNIK DAVID J
发明人： BETEBENNER DAVID A , DEGOEY DAVID A , MARING CLARENCE J , KRUEGER ALLAN C , IWASAKI NOBUHIKO , ROCKWAY TODD W , COOPER CURT S , ANDERSON DAVID D , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , LIU DACHUN , MCDANIEL KEITH F , MADIGAN DAROLD L , MOTTER CHRISTOPHER E , PRATT JOHN K , SHANLEY JASON P , TUFANO MICHAEL D , WAGNER ROLF , ZHANG RONG , MOLLA AKHTERUZZAMAN , MO HONGMEI , PILOT-MATIAS TAMI J , MASSE SHERIE VL , CARRICK ROBERT J , HE WEPING , LU LIANGJUN , GRAMPOVNIK DAVID J
IPC分类号： C07D495/04 , C07D471/04 , C07D513/04
CPC分类号： C07D487/04 , C07D471/04 , C07D475/06 , C07D495/04 , C07D513/04
摘要： Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

8. 发明申请

WO2008133753A3 ANTI-VIRAL COMPOUNDS 审中-公开
标题翻译：抗病毒化合物
公开(公告)号：WO2008133753A3
公开(公告)日：2008-12-24
申请号：PCT/US2007088027
申请日：2007-12-19
申请人： ABBOTT LAB , BETEBENNER DAVID A , MARING CLARENCE J , ROCKWAY TODD W , COOPER CURT S , ANDERSON DAVID D , WAGNER ROLF , ZHANG RONG , MOLLA AKHTERUZZAMAN , MO HONGMEI , PILOT-MATIAS TAMI J , MASSE SHERIE VL , CARRICK ROBERT J , HE WENPING , LU LIANGJUN
发明人： BETEBENNER DAVID A , MARING CLARENCE J , ROCKWAY TODD W , COOPER CURT S , ANDERSON DAVID D , WAGNER ROLF , ZHANG RONG , MOLLA AKHTERUZZAMAN , MO HONGMEI , PILOT-MATIAS TAMI J , MASSE SHERIE VL , CARRICK ROBERT J , HE WENPING , LU LIANGJUN
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： C07D471/04 , C07D239/94 , C07D487/04 , C07D487/14 , C07D519/00
摘要： Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
摘要翻译：公开了有效抑制丙型肝炎病毒（HCV）或其他病毒复制的化合物。本发明还涉及包含此类化合物的组合物，这类化合物与其它抗病毒剂或治疗剂的共配制或共同施用，用于合成这些化合物的方法和中间体，以及使用此类化合物治疗HCV或其他病毒感染。

9. 发明申请

WO2007076034A3 ANTI-VIRAL COMPOUNDS 审中-公开
公开(公告)号：WO2007076034A3
公开(公告)日：2007-10-04
申请号：PCT/US2006049079
申请日：2006-12-20
申请人： ABBOTT LAB , BETEBENNER DAVID A , DEGOEY DAVID A , MARING CLARENCE J , KRUEGER ALLAN C , IWASAKI NOBUHIKO , ROCKWAY TODD W , COOPER CURT S , ANDERSON DAVID D , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , LIU DACHUN , MCDANIEL KEITH F , MADIGAN DAROLD L , MOTTER CHRISTOPHER E , PRATT JOHN K , SHANLEY JASON P , TUFANO MICHAEL D , WAGNER ROLF , ZHANG RONG , MOLLA AKHTERUZZAMAN , MO HONGMEI , PILOT-MATIAS TAMI J , MASSE SHERIE VL , CARRICK ROBERT J , HE WEPING , LU LIANGJUN , GRAMPOVNIK DAVID J
发明人： BETEBENNER DAVID A , DEGOEY DAVID A , MARING CLARENCE J , KRUEGER ALLAN C , IWASAKI NOBUHIKO , ROCKWAY TODD W , COOPER CURT S , ANDERSON DAVID D , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , LIU DACHUN , MCDANIEL KEITH F , MADIGAN DAROLD L , MOTTER CHRISTOPHER E , PRATT JOHN K , SHANLEY JASON P , TUFANO MICHAEL D , WAGNER ROLF , ZHANG RONG , MOLLA AKHTERUZZAMAN , MO HONGMEI , PILOT-MATIAS TAMI J , MASSE SHERIE VL , CARRICK ROBERT J , HE WEPING , LU LIANGJUN , GRAMPOVNIK DAVID J
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , C07D495/04 , C07D513/04
摘要： Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

10. 发明申请

WO1995021922A2 NON-A, NON-B, NON-C, NON-D, NON-E HEPATITIS REAGENTS AND METHODS FOR THEIR USE 审中-公开
标题翻译： NON-A，NON-B，N-C，N-D，非E型乙型肝炎试剂及其使用方法
公开(公告)号：WO1995021922A2
公开(公告)日：1995-08-17
申请号：PCT/US1995002118
申请日：1995-02-14
申请人： ABBOTT LABORATORIES , SIMONS, John, N. , PILOT-MATIAS, Tami, J. , DAWSON, George, J. , SCHLAUDER, George, G. , DESAI, Suresh, M. , LEARY, Thomas, P. , MUERHOFF, Anthony, Scott , ERKER, James, Carl , BUIJK, Sheri, L. , MUSHAHWAR, Isa, K.
发明人： ABBOTT LABORATORIES
IPC分类号： C12N15/51
CPC分类号： C07K14/005 , A61K39/00 , C07K16/109 , C07K2319/00 , C12N2770/24222 , C12Q1/707 , G01N33/576
摘要： Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.
摘要翻译：用于各种诊断和治疗应用的乙型肝炎病毒（HGBV）核酸和氨基酸序列，使用HGBV核酸或氨基酸序列的试剂盒，HGBV免疫原性颗粒和特异性结合HGBV的抗体。还提供了从HGBV核酸或氨基酸序列产生抗体，多克隆或单克隆抗体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式